Overview

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

Study to evaluate the safety and efficacy of oral CEM-101 compared to oral Levofloxacin in the treatment of adults with moderate to moderately severe community-acquired bacterial pneumonia.

Phase:

Phase 2

Details

Lead Sponsor:

Cempra Inc
Melinta Therapeutics, Inc.

Treatments:

Levofloxacin
Ofloxacin
Solithromycin